earnings
VR
NASDAQ · VRCA
Verrica Pharmaceuticals Inc.
Healthcare · Biotechnology
$4.91
Down-$0.04 (-0.81%)
Updated Sep 12, 2026, 3:17 PM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 79.81M
- P/E ratio
- -3.07
- Dividend yield
- 0.00%
- 52-week range
- $4.25 – $8.50
- Volume
- 41.89K
- Avg. volume
- 399.36K
Price performance
VRCA price history
1M range · 20 trading sessions · Daily adjusted prices
VRCA closed at $4.91 after 20 trading sessions, down 1.21% for the selected period.
- Last close
- $4.91
- Period change
- -1.21%
- Period low
- $4.68
- Period high
- $5.69
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $4.99 | $5.03 | $4.80 | $4.91 | 41.89K |
| Sep 10, 2026 | $5.06 | $5.25 | $4.86 | $4.95 | 56.97K |
| Sep 9, 2026 | $5.25 | $5.40 | $5.05 | $5.06 | 47.81K |
| Sep 8, 2026 | $5.30 | $5.4144 | $5.04 | $5.26 | 112.2K |
| Sep 4, 2026 | $5.28 | $5.525 | $5.25 | $5.30 | 12.2K |
| Sep 3, 2026 | $5.48 | $5.63 | $5.27 | $5.36 | 55.39K |
| Sep 2, 2026 | $5.32 | $5.56 | $5.2837 | $5.39 | 31.08K |
| Sep 1, 2026 | $5.36 | $5.56 | $5.22 | $5.24 | 43.49K |
| Aug 31, 2026 | $5.70 | $5.8308 | $5.295 | $5.46 | 106.42K |
| Aug 28, 2026 | $5.12 | $5.86 | $5.00 | $5.69 | 351.92K |
| Aug 27, 2026 | $5.01 | $5.65 | $4.90 | $5.07 | 533.71K |
| Aug 26, 2026 | $4.86 | $5.055 | $4.84 | $4.91 | 27.66K |
| Aug 25, 2026 | $4.90 | $4.99 | $4.75 | $4.94 | 54.91K |
| Aug 24, 2026 | $4.81 | $4.9499 | $4.61 | $4.87 | 67.96K |
| Aug 21, 2026 | $4.90 | $4.99 | $4.64 | $4.82 | 78.82K |
| Aug 20, 2026 | $4.99 | $5.1811 | $4.83 | $4.86 | 138.48K |
| Aug 19, 2026 | $5.22 | $5.22 | $4.77 | $4.99 | 169.81K |
| Aug 18, 2026 | $4.90 | $5.00 | $4.68 | $4.68 | 50.3K |
| Aug 17, 2026 | $5.00 | $5.15 | $4.7651 | $4.89 | 179.72K |
| Aug 14, 2026 | $4.89 | $5.0983 | $4.78 | $4.97 | 59.64K |
Latest VRCA news
The latest Smart Investors Daily articles mentioning VRCA.
Stock researchResearch & News · SEC Filings
Loading stock research…